Frontlight ResearchEarly access
Ovarian cancer trials in Japan
49 trials · From ClinicalTrials.gov, checked 16 November 2026. Ask the study team whether a trial fits you.
- Phase 1Taking peopleStudy to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- Where
- Chuo-Ku, Kashiwa-shi, Koto-ku, Kyoto, Nagoya, Sunto-gun
- Age
- 18 years and over
- People
- 325 worldwide
- Run by
- AbbVie
See details and how to joinNCT06084481 · EU 2023-506227-29-00 - Phase 1/2Taking peopleA Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Where
- Chūōku, Hidaka-shi, Kashiwa, Kōtoku, Kurume-shi, Sunto-gun
- Age
- 18 years and over
- People
- 460 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05123482 · EU 2022-502759-70-01 - Phase 1Taking peopleA Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
- Where
- Hidaka, Kashiwa-shi, Sunto-gun
- Age
- 18 years and over
- People
- 285 worldwide
- Run by
- AbbVie
See details and how to joinNCT07278336 · EU 2025-522209-40-00 - Phase 1/2Taking peopleA Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Where
- Chūōku, Kashiwa
- Age
- 18 years and over
- People
- 120 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07115043 - Phase 1Taking peopleA Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
- Where
- Chuo Ku, Hirakata, Kashiwa, Koto-ku
- Age
- 18 years and over
- People
- 234 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06997029 · EU 2025-524334-26-01 - Phase 3Taking peopleStudy to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
- Where
- Akashi, Hidaka, Kashiwa, Kawasaki, Kurume, Nagaizumi-chō, Niigata, Okayama, Sagamihara, Sapporo, Sendai, Takatsuki, Tokyo, Tsu, Yokohama
- Age
- 18 years and over
- People
- 544 worldwide
- Run by
- Genmab
See details and how to joinNCT07225270 · EU 2025-522167-15-00 - Phase 1/2Taking peoplePhase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Where
- Hidaka-shi, Kashiwa, Kōtoku, Sunto-gun, Tokyo
- Age
- 18 years to 130 years
- People
- 622 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05797168 · EU 2022-502576-23-00 - Phase 2Taking peopleA Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
- Where
- Akashi-shi, Chuo-Ku, Koto-ku
- Age
- 18 years and over
- People
- 377 worldwide
- Run by
- AbbVie
See details and how to joinNCT07024784 - Phase 3Taking peopleA Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)
- Where
- Hokkaido, Hyōgo, Ibaraki
- Age
- 18 years and over
- People
- 690 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07684612 · EU 2025-523366-24-00 - Phase 2Taking peopleStudy of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Where
- Chūōku, Kashiwa, Kōtoku, Nagoya, Shinagawa-ku, Suita-shi
- Age
- 18 years to 130 years
- People
- 454 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00 - Phase 1Taking peopleEvaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Where
- Chūōku
- Age
- 18 years and over
- People
- 540 worldwide
- Run by
- SystImmune Inc.
See details and how to joinNCT05983432 - Phase 2Taking peopleA Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Where
- Akashi-shi, Hidaka-shi, Kōtoku, Kurume, Matsuyama, Sapporo, Sunto-gun
- Age
- 18 years to 99 years
- People
- 160 worldwide
- Run by
- Incyte Corporation
See details and how to joinNCT07023627 · EU 2025-521513-14-00 - Phase 3Taking peopleActive Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
- Where
- Chiba-sgi, Chuo-ku, Higashiku, Hiroshima, Kobe, Kyoto, Niigata, Nishinomiya, Hyogo, Osaka, Saitama, Sapporo, Sendai, Shinjuku-ku, Tokyo, Tsukuba, Yokohama
- People
- 1,780 worldwide
- Run by
- Children's Oncology Group
See details and how to joinNCT03067181 - Phase 1Taking peopleA Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)
- Where
- Chiba, Kashiwa, Tokyo, Koto-ku
- Age
- 18 years and over
- People
- 187 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07306559 · EU 2025-522913-45-00 - Phase 1/2Taking peopleA Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- Where
- Kashiwa
- Age
- 18 years and over
- People
- 1,109 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT04895709 - Phase 3Taking peopleUtility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery
- Where
- Bunkyō City, Fukushima, Hidaka, Hirosaki, Kashiwa, Kawasaki, Koshigaya, Kurume, Nagoya, Sayama, Sendai, Takatsuki, Tokyo
- Age
- 18 years and over
- People
- 250 worldwide
- Run by
- ARCAGY/ GINECO GROUP
See details and how to joinNCT06476184 - Phase 3Taking peopleAZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
- Where
- Akashi-shi, Chūōku, Hidaka-shi, Kashiwa, Kobe, Kōtoku, Kurume-shi, Nagoya, Niigata, Okayama, Osaka, Sagamihara-shi, Sapporo, Sendai, Shinjuku-ku, Shiwa-gun, Sunto-gun, Toon-Shi, Tsu
- Age
- 18 years and over
- People
- 1,100 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07218809 · EU 2025-520466-22-00 - Phase 1/2Taking peopleFirst-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Where
- Fukuoka, Hirakata, Kōtō City, Kyoto
- Age
- 18 years and over
- People
- 880 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT05768139 · EU 2023-504807-94-00 - Phase 1Taking peopleStudy to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Where
- Chuo-ku, Hirakata-shi, Kashiwa-shi, Kobe, Nagoya, Sunto-gun, Wakayama
- Age
- 18 years and over
- People
- 694 worldwide
- Run by
- AbbVie
See details and how to joinNCT05005403 - Phase 1/2Taking peopleA Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
- Where
- Chuo Ku, Koto-Ku
- Age
- 18 years and over
- People
- 182 worldwide
- Run by
- Eisai Inc.
See details and how to joinNCT04300556 · EU 2023-506868-14-00 - Phase 2Taking peopleNiraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer
- Where
- Ehime, Kashiwanoha, Kita-ku, Kurume, Niigata, Saitama, Shimotsuke, Tokyo, Tsukuba, Yamagata
- Age
- 18 years to 99 years
- People
- 390 worldwide
- Run by
- ARCAGY/ GINECO GROUP
See details and how to joinNCT05183984 · EU 2023-504166-37-00 - No phaseTaking peopleProspective Cohort Study of Germline Variant Carriers With BRCA1 or BRCA2
- Where
- Okayama
- Age
- 20 years and over
- People
- 600
- Run by
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
See details and how to joinNCT03296826 - Phase 1/2Taking peopleA Study of MT-4561 in Patients With Various Advanced Solid Tumors
- Where
- Chuo Ku, City
- Age
- 18 years and over
- People
- 27 worldwide
- Run by
- Tanabe Pharma America, Inc.
See details and how to joinNCT06943521 - Phase 3Taking peoplePhase III Trial of Stage I Ovarian Cancer After Surgery
- Where
- Akashi-shi, Amagasaki-shi, Arakawa City, Bunkyo-ku, Bunkyō-Ku, Chiyoda City, Fuchu-shi, Fukuoka, Gifu, Hakodate-shi, Hatsukaichi-shi, Hidaka-shi, Himeji-shi, Hirosaki-shi, Hiroshima, Isehara-Shi, Ise-shi, Izumo, Kagoshima, Kaizuka, Kashiwa-shi, Katsushika-ku, Kawasaki-shi, Kobe, Komae-shi, Koshigaya-shi, Koto-Ku, Kumamoto, Kurume-shi, Kyoto, Maebashi, Matsumoto-shi, Matsuyama, Matsuzaka, Meguro-ku, Mibu, Minato-ku, Miyoshi-shi, Morioka, Nagaizumi-chō, Nagakute-shi, Nagano, Nagasaki, Nagoya, Nakagami-gun, Nara, Niigata, Onsen-gun, Osaka, Osaka Sayama Shi, Ōta, Saga, Sagamihara, Saitama, Sakai, Sapporo, Sendai, Seto-shi, Shimotsuke-shi, Shinden, Shinjuku-ku, Shizuoka, Shunan-shi, Suginami, Suita-shi, Tachikawa-shi, Takatsuki-shi, Tokorozawa-shi, Tokushima, Tomishiro-shi, Tottori-shi, Toyoake-shi, Tsu, Tsukuba, Uruma, Wako, Yamagata, Yamaguchi, Yokohama, Yonago-shi, Yufu
- Age
- 20 years and over
- People
- 360 worldwide
- Run by
- Japanese Gynecologic Oncology Group
See details and how to joinNCT04063527